JMD GMP oligos for in vitro Diagnostics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Originally published online as doi:10.2353/jmoldx.2009.090032 on July 30, 2009

Published online before print July 30, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jmoldx.2009.090032v1
11/5/415    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by De Leeneer, K.
Right arrow Articles by Claes, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Leeneer, K.
Right arrow Articles by Claes, K.
Journal of Molecular Diagnostics 2009, Vol. 11, No. 5
Copyright © 2009 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2009.090032


Technical Advances

Genotyping of Frequent BRCA1/2 SNPs with Unlabeled Probes

A Supplement to HRMCA Mutation Scanning, Allowing the Strong Reduction of Sequencing Burden

Kim De Leeneer, Ilse Coene, Bruce Poppe, Anne De Paepe and Kathleen Claes

From the Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium

We previously validated mutation scanning for BRCA1 and 2 using high-resolution melting curve analysis (HRMCA). Due to recurrent single nucleotide polymorphisms (SNPs), a considerable amount of sequencing work remains after HRMCA, as melting curves for SNPs and deleterious mutations may be similar. Here, we present a simple approach for the optimization of SNP genotyping with HRMCA using unlabeled probes. Protocols were optimized for 14 frequent SNPs in BRCA1 and 2. Two probes contained an additional mismatch to detect a rare polymorphism a few nucleotides upstream. PCR was performed in the presence of LCgreenPlus and analyzed on a Lightscanner. Genotyping assays were optimized with five wild-type, heterozygous, and homozygous mutant samples. Sensitivity and specificity of the assays were evaluated with a blind screening of 95 samples. All unlabeled probes correctly genotyped the SNPs. A 1:5 asymmetric primer ratio produced sufficient probe-strand duplexes to accurately genotype the SNP of interest. The most important parameter to optimize was the number of PCR cycles. By complementing our BRCA1/2 HRMCA with 14 unlabeled probe assays, we reduced the sequencing burden by three-fold. Our simple approach for optimization can be used as a blueprint to design genotyping assays for other genes. This is one of the largest studies reported to date and the first that presents an approach combining genotyping and mutation scanning of two large polymorphic genes.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society for Investigative Pathology and the Association for Molecular Pathology.